MINNEAPOLIS, June 11, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has established a new partnership with ZERO – The End of ...

NEW YORK--(BUSINESS WIRE)--Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world ...

MINNEAPOLIS, March 23, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has completed its clinical validation of an in vitro ...

Janssen has tapped Resolution Bioscience to help develop a companion liquid biopsy test for the PARP inhibitor Zejula (niraparib) in patients with metastatic castration-resistant prostate cancer.

• Applications of germline genetic testing, tumor genomics, and other biomarkers are now routinely used in risk assessment, determination of treatment course, prognosis, and monitoring. • Imaging ...

Cancer trial matchmaker Massive Bio is teaming up with two organizations to boost clinical studies and research participation for prostate cancer. Massive Bio, Veterans Prostate Cancer Awareness and ...

CDX Prostate is a blood-based diagnostic tool that uses AI-powered learning to determine the risk of aggressive prostate cancer. Florida-based Protean BioDiagnostics will now offer the validated CDX ...

Scientists at Duke University School of Medicine in Durham, North Carolina, have developed a small-molecule inhibitor of the cellular stress-protective transcription factor, heat shock factor 1 (HSF1) ...

A Point Biopharma Global cancer therapy key to a $1.4 billion Eli Lilly M&A deal has met the main goal of its pivotal clinical trial in prostate cancer. But the results raise questions about how well ...